Characteristics of trials and regulatory pathways leading to US approval of innovative vs. non-innovative oncology drugs

Kerstin Noëlle Vokinger and Aaron S. Kesselheim

Health Policy, 2019, vol. 123, issue 8, 721-727

Abstract: Successful first-generation drugs can be converted with small alterations to "second-generation drugs," which are cheaper to develop and may pose less financial risk for manufacturers due to already validated action mechanism and a well-defined consumer market.

Keywords: Health policy; Public health; First-generation drug; Second generation drug; Drug approval; Cancer (search for similar items in EconPapers)
Date: 2019
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
http://www.sciencedirect.com/science/article/pii/S0168851019301538
Full text for ScienceDirect subscribers only

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:eee:hepoli:v:123:y:2019:i:8:p:721-727

DOI: 10.1016/j.healthpol.2019.06.002

Access Statistics for this article

Health Policy is currently edited by Katrien Kesteloot, Mia Defever and Irina Cleemput

More articles in Health Policy from Elsevier
Bibliographic data for series maintained by Catherine Liu () and ().